Citations

Citations to this article as recorded by  

• Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer
  Xi Ding, Min-xing Shi, Di Liu, Jing-xue Cao, Kai-xuan Zhang, Run-dong Zhang, Li-ping Zhang, Kai-xing Ai, Bo Su, Jie Zhang
  Cell Communication and Signaling.2024;[Epub]     CrossRef
• The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies
  Alessandra Ferro, Gian Marco Marinato, Cristiana Mulargiu, Monica Marino, Giulia Pasello, Valentina Guarneri, Laura Bonanno
  Critical Reviews in Oncology/Hematology.2024; 196: 104295.     CrossRef
• Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report
  Kresimir Tomic, Kristina Krpina, Lara Baticic, Miroslav Samarzija, Semir Vranic
  Journal of Drug Targeting.2024; : 1.     CrossRef
• Exon-18-EGFR Mutated Transformed Small-Cell Lung Cancer: A Case Report and Literature Review
  Nunzio Digiacomo, Tommaso De Pas, Giovanna Rossi, Paola Bossi, Erika Stucchi, Fabio Conforti, Emilia Cocorocchio, Daniele Laszlo, Laura Pala, Emma Zattarin, Chiara Catania
  Current Oncology.2023; 30(3): 3494.     CrossRef
• Current knowledge of small cell lung cancer transformation from non-small cell lung cancer
  Giuseppe Giaccone, Yongfeng He
  Seminars in Cancer Biology.2023; 94: 1.     CrossRef
• Targeting the EGFR signaling pathway in cancer therapy: What’s new in 2023?
  Sushanta Halder, Soumi Basu, Shobhit P. Lall, Apar K. Ganti, Surinder K. Batra, Parthasarathy Seshacharyulu
  Expert Opinion on Therapeutic Targets.2023; 27(4-5): 305.     CrossRef
• Outcomes in Patients With Lung Adenocarcinoma With Transformation to Small Cell Lung Cancer After EGFR Tyrosine Kinase Inhibitors Resistance: A Systematic Review and Pooled Analysis
  Jinhe Xu, Lihuan Xu, Baoshan Wang, Wencui Kong, Ying Chen, Zongyang Yu
  Frontiers in Oncology.2022;[Epub]     CrossRef
• Small cell lung cancer transformation: From pathogenesis to treatment
  Xiaomeng Yin, Yueyi Li, Hang Wang, Tingting Jia, Enli Wang, Yuling Luo, Yuhao Wei, Zeyi Qin, Xuelei Ma
  Seminars in Cancer Biology.2022; 86: 595.     CrossRef
• Small Cell Lung Cancer Transformation following Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
  Isa Mambetsariev, Leonidas Arvanitis, Jeremy Fricke, Rebecca Pharaon, Angel R. Baroz, Michelle Afkhami, Marianna Koczywas, Erminia Massarelli, Ravi Salgia
  Journal of Clinical Medicine.2022; 11(5): 1429.     CrossRef
• Morphologic-Molecular Transformation of Oncogene Addicted Non-Small Cell Lung Cancer
  Fiorella Calabrese, Federica Pezzuto, Francesca Lunardi, Francesco Fortarezza, Sofia-Eleni Tzorakoleftheraki, Maria Vittoria Resi, Mariaenrica Tiné, Giulia Pasello, Paul Hofman
  International Journal of Molecular Sciences.2022; 23(8): 4164.     CrossRef
• Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets
  Ugo Testa, Elvira Pelosi, Germana Castelli
  Onco.2022; 2(3): 186.     CrossRef
• Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon
  Xiao Chu, Yuyin Xu, Ye Li, Yue Zhou, Li Chu, Xi Yang, Jianjiao Ni, Yida Li, Tiantian Guo, Zhiqin Zheng, Qiang Zheng, Qianlan Yao, Yuan Li, Xiaoyan Zhou, Zhengfei Zhu
  Lung Cancer.2022; 169: 22.     CrossRef
• Three Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer: Similarities and Differences
  Ling Chen, Yangqingqing Zhou, Chaosheng Gan, XiaoLi Wang, Yihui Liu, Chunhui Dong, Ruiyuan He, Jin Yang
  Cancer Investigation.2022; 40(7): 590.     CrossRef
• Histomorphological transformation from non-small cell lung carcinoma to small cell lung carcinoma after targeted therapy or immunotherapy: A report of two cases
  Hao Liu, Li-Hong Chen, Zhi-Hui Zhang, Ning Wang, Si-Hui Zhuang, Hao Chen, Jin Du, Li-Juan Pang, Yan Qi
  Frontiers in Oncology.2022;[Epub]     CrossRef
• Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient
  Maurício Fernando Silva Almeida Ribeiro, Franciele Hinterholz Knebel, Fabiana Bettoni, Rodrigo Saddi, Karina Perez Sacardo, Felipe Sales Nogueira Amorim Canedo, João Victor Machado Alessi, Andrea Kazumi Shimada, José Flávio Gomes Marin, Anamaria Aranha Ca
  npj Precision Oncology.2021;[Epub]     CrossRef
• Histological transformation of non-small cell lung cancer: Clinical analysis of nine cases
  Cai-Bao Jin, Ling Yang
  World Journal of Clinical Cases.2021; 9(18): 4617.     CrossRef
• Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor
  Naoyuki Nishiya, Yusuke Oku, Chie Ishikawa, Tsutomu Fukuda, Shingo Dan, Tetsuo Mashima, Masaru Ushijima, Yoko Furukawa, Yuka Sasaki, Keishi Otsu, Tomoko Sakyo, Masanori Abe, Honami Yonezawa, Fumito Ishibashi, Masaaki Matsuura, Akihiro Tomida, Hiroyuki Sei
  Cancer Science.2021; 112(5): 1963.     CrossRef
• Case Report: Transformation From Non-Small Cell Lung Cancer to Small Cell Lung Cancer During Anti-PD-1 Therapy: A Report of Two Cases
  Qian Shen, Jingjing Qu, Lingyan Sheng, Qiqi Gao, Jianying Zhou
  Frontiers in Oncology.2021;[Epub]     CrossRef
• Exploring the resistance mechanisms of second-line osimertinib and their prognostic implications using next-generation sequencing in patients with non-small-cell lung cancer
  Kyoungmin Lee, Deokhoon Kim, Shinkyo Yoon, Dae Ho Lee, Sang-We Kim
  European Journal of Cancer.2021; 148: 202.     CrossRef
• Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma
  Shouzheng Wang, Tongji Xie, Xuezhi Hao, Yan Wang, Xingsheng Hu, Lin Wang, Yan Li, Junling Li, Puyuan Xing
  Thoracic Cancer.2021; 12(19): 2585.     CrossRef
• EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs
  Chih-An Lin, Sung-Liang Yu, Hsuan-Yu Chen, Huei-Wen Chen, Shr-Uen Lin, Chia-Ching Chang, Chong-Jen Yu, Pan-Chyr Yang, Chao-Chi Ho
  Journal of Thoracic Oncology.2019; 14(3): 513.     CrossRef
• The clinicopathologic of pulmonary adenocarcinoma transformation to small cell lung cancer
  Haiyan Yang, Li Liu, Chunhua Zhou, Yi Xiong, Yijuan Hu, Nong Yang, Jingjing Qu
  Medicine.2019; 98(12): e14893.     CrossRef
• Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents
  Olayinka O. Ajani, Martins T. Nlebemuo, Joseph A. Adekoya, Kehinde O. Ogunniran, Tolutope O. Siyanbola, Christiana O. Ajanaku
  Acta Pharmaceutica.2019; 69(2): 177.     CrossRef
• Resistance to EGFR inhibitors in non-small cell lung cancer: Clinical management and future perspectives
  Chiara Tomasello, Cinzia Baldessari, Martina Napolitano, Giulia Orsi, Giulia Grizzi, Federica Bertolini, Fausto Barbieri, Stefano Cascinu
  Critical Reviews in Oncology/Hematology.2018; 123: 149.     CrossRef
• Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review
  Yangyang Liu
  Cancer Biology & Therapy.2018; 19(6): 445.     CrossRef
• Anaplastic lymphoma kinase (ALK)-expressing Lung Adenocarcinoma with Combined Neuroendocrine Component or Neuroendocrine Transformation: Implications for Neuroendocrine Transformation and Response to ALK-tyrosine Kinase Inhibitors
  Jongmin Sim, Hyunjin Kim, Jiyeon Hyeon, Yoon-La Choi, Joungho Han
  Journal of Korean Medical Science.2018;[Epub]     CrossRef
• Assessment of Resistance Mechanisms and Clinical Implications in Patients WithEGFRT790M–Positive Lung Cancer and Acquired Resistance to Osimertinib
  Geoffrey R. Oxnard, Yuebi Hu, Kathryn F. Mileham, Hatim Husain, Daniel B. Costa, Philip Tracy, Nora Feeney, Lynette M. Sholl, Suzanne E. Dahlberg, Amanda J. Redig, David J. Kwiatkowski, Michael S. Rabin, Cloud P. Paweletz, Kenneth S. Thress, Pasi A. Jänne
  JAMA Oncology.2018; 4(11): 1527.     CrossRef
• Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer
  Mong-Wei Lin, Kang-Yi Su, Te-Jen Su, Chia-Ching Chang, Jing-Wei Lin, Yi-Hsuan Lee, Sung-Liang Yu, Jin-Shing Chen, Min-Shu Hsieh
  Lung Cancer.2018; 125: 282.     CrossRef
• Transformation to small‑cell lung cancer following treatment with icotinib in a patient with lung adenocarcinoma
  Hongyang Lu, Bo Chen, Jing Qin, Fajun Xie, Na Han, Zhiyu Huang
  Oncology Letters.2018;[Epub]     CrossRef
• Histological transformation of adenocarcinoma to small cell carcinoma lung as a rare mechanism of resistance to epidermal growth factor receptor-tyrosine kinase inhibitors: Report of a case with review of literature
  Monalisa Hui, ShantveerG Uppin, BalaJoseph Stalin, G Sadashivudu
  Lung India.2018; 35(2): 160.     CrossRef
• A rare case of squamous cell carcinoma lung with multiple locoregional recurrences and histological transformation
  Ram Niwas, Shibdas Chakrabarti, Viswesvaran Balasubramanian, ManasKamal Sen, JagdishChander Suri
  Lung India.2018; 35(6): 511.     CrossRef
• Small cell lung cancer transformation during immunotherapy with nivolumab: A case report
  Takuma Imakita, Kohei Fujita, Osamu Kanai, Tsuyoshi Terashima, Tadashi Mio
  Respiratory Medicine Case Reports.2017; 21: 52.     CrossRef
• Pulmonary neuroendocrine tumor in a female wolf (Canis lupus lupus)
  Ayako SHIRAKI, Toshinori YOSHIDA, Masahi KAWASHIMA, Hirotada MURAYAMA, Rei NAGAHARA, Nanao ITO, Makoto SHIBUTANI
  Journal of Veterinary Medical Science.2017; 79(3): 588.     CrossRef
• Secondary biopsy of non‐oncogenic‐driven lung cancer may reveal a clinically sensible histologic change. A brief report of two paradigmatic cases
  Maria C. Mengoli, Giulia Orsi, Filippo Lococo, Giulia Grizzi, Fausto Barbieri, Federica Bertolini, Giulio Rossi, Silvia Novello
  Thoracic Cancer.2017; 8(4): 359.     CrossRef
• Small-cell lung cancer in never smokers: The clinicopathological features including the prognosis
  Masahiro Yamasaki, Naomi Saito, Wakako Daido, Sayaka Ishiyama, Naoko Deguchi, Masaya Taniwaki, Akio Sakatani, Megumu Fujihara, Nobuyuki Ohashi, Ken-ichi Arita
  Cancer Treatment and Research Communications.2017; 12: 1.     CrossRef
• Clonal History and Genetic Predictors of Transformation Into Small-Cell Carcinomas From Lung Adenocarcinomas
  June-Koo Lee, Junehawk Lee, Sehui Kim, Soyeon Kim, Jeonghwan Youk, Seongyeol Park, Yohan An, Bhumsuk Keam, Dong-Wan Kim, Dae Seog Heo, Young Tae Kim, Jin-Soo Kim, Se Hyun Kim, Jong Seok Lee, Se-Hoon Lee, Keunchil Park, Ja-Lok Ku, Yoon Kyung Jeon, Doo Hyun
  Journal of Clinical Oncology.2017; 35(26): 3065.     CrossRef
• Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer
  Thomas John, Jeffrey J Bowden, Stephen Clarke, Stephen B Fox, Kerryn Garrett, Keith Horwood, Christos S Karapetis
  Asia-Pacific Journal of Clinical Oncology.2017; 13(4): 296.     CrossRef
• Metastatic Squamous Cell Carcinoma from Lung Adenocarcinoma after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy
  Hyung Kyu Park, Youjeong Seo, Yoon-La Choi, Myung-Ju Ahn, Joungho Han
  Journal of Pathology and Translational Medicine.2017; 51(4): 441.     CrossRef
• Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
  Ahsan Wahab, Kavitha Kesari, Siddique Chaudhary, Mahin Khan, Hafiz Khan, Susan Smith, Yanis Boumber
  Cancer Biology & Therapy.2017; 18(12): 940.     CrossRef
• The expression of S100B protein in serum of patients with brain metastases from small-cell lung cancer and its clinical significance
  Shanling Mu, Hong Ma, Jun Shi, Dezhi Zhen
  Oncology Letters.2017;[Epub]     CrossRef